Instrument Inactif

Autres langues Chromadex Corp OTC Bulletin Board

Actions

CDXC

US1710771007

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

06/08	Niagen Bioscience, Inc. lance Tru Niagen sur Walmart.com, renforçant son accessibilité et diversifiant sa présence sur le marché du commerce électronique	CI
04/08	Transcript : Niagen Bioscience, Inc., Q2 2026 Earnings Call, Aug 04, 2026

Autres langues

06/08	Niagen Bioscience, Inc. Launches Tru Niagen On Walmart.com, Expanding Access And Diversifying Its E-Commerce Marketplace Presence
06/08	Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
05/08	Niagen Bioscience : Second Quarter 2026 Presentation
04/08	Niagen Bioscience: Q2 Earnings Snapshot
04/08	Niagen Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
03/08	Niagen Bioscience, Evotec to Advance Preclinical Development of NB4168
03/08	Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
28/07	Niagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference
28/07	Niagen Bioscience Announces Newly Published Analysis Demonstrating Niagen Supplementation Improves Muscle-Specific Marker of Biological Aging
28/07	Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
27/07	Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
21/07	Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
16/07	Niagen Bioscience, Inc. Announces Appointment of Abhijit Kale as Senior Director of Global External Research, Effective July 20, 2026
16/07	Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
13/07	Niagen Bioscience Receives U.S. Fda Rare Pediatric Disease Designation and European Medicines Agency Orphan Medicinal Product Designation for Nb4168 for Treatment of Ataxia Telangiectasia
13/07	Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia
13/07	Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
09/07	Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
08/07	Niagen Bioscience Launches Pharmaceutical Program And Advances NB4168 As First Drug Candidate For Accelerated Aging And Rare Genetic Diseases
08/07	Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases
08/07	Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
03/06	Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
02/06	Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
21/05	NARB recommends Niagen modify/discontinue certain Tru Niagen NAD+ dietary supplement claims